Cervical Cancer Shots Backed by Major New Review

Cervical Cancer Shots Backed by Major New Review


Vaccines designed to prevent infection with human papillomavirus (HPV) are effective in protecting against pre-cancerous cervical lesions in women, particularly in those vaccinated between age 15 and 26, according to a large international evidence review.
The research by scientists at the respected scientific network the Cochrane Review also found no increase in the risk of serious side effects, with rates of around 7 percent reported by both HPV-vaccinated and control groups. > >> read more ...

Marijuana-Based Drug Gets Positive Review From US Agency

Marijuana-Based Drug Gets Positive Review From US Agency


The FDA gave a marijuana-based drug a positive review Tuesday, when health officials said the closely watched medicine reduces seizures in children with severe forms of epilepsy and warrants approval in the United States.

British drugmaker GW Pharmaceuticals is seeking permission to sell its purified form of an ingredient found in cannabis — one that doesn’t get users high — as a medication for rare, hard-to-treat seizures in children. If successful, the company’s liquid formula would be the first government-approved drug derived from the cannabis plant in the U.S. > >> read more ...

Cannabis-Based Epilepsy Drug Gets Positive Review: FDA

Cannabis-Based Epilepsy Drug Gets Positive Review: FDA


GW Pharmaceuticals’ cannabis-derived medicine for severe childhood epilepsy won a favorable review from U.S. Food and Drug Administration (FDA) staff on Tuesday, boosting hopes for its approval in the world’s biggest drugs market.

Shares in the company, which has operations in Britain and the United States, were 11 percent higher in early Nasdaq trade on the news.

GW’s medicine Epidiolex, which is given as a syrup, is a purified form of cannabidiol, one of the active ingredients found in marijuana. It contains less than 0.1 percent of tetrahydrocannabinol, the substance that makes people high. > >> read more ...

FDA Sued Over Delay in E-Cigarette Review

FDA Sued Over Delay in E-Cigarette Review


Several anti-smoking groups are suing the Food and Drug Administration over a decision by Trump administration officials to delay the review of e-cigarettes.

The lawsuit filed Tuesday in federal court argues that the FDA didn’t follow proper requirements last year when it decided to push back the deadline for makers of e-cigarettes to submit their products for review. The groups say the delay poses a threat to children’s health.

“The FDA offered no meaningful justification for ripping a hole in the statutory framework,” according to the lawsuit filed by the American Heart Association, the American Academy of Pediatrics, the Campaign for Tobacco-Free Kids and others. > >> read more ...